Future Fund LLC Purchases 350 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Future Fund LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.6% during the fourth quarter, HoldingsChannel reports. The firm owned 2,052 shares of the pharmaceutical company’s stock after buying an additional 350 shares during the period. Vertex Pharmaceuticals comprises approximately 2.4% of Future Fund LLC’s portfolio, making the stock its 22nd largest holding. Future Fund LLC’s holdings in Vertex Pharmaceuticals were worth $826,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Dunhill Financial LLC increased its holdings in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. Simon Quick Advisors LLC grew its position in shares of Vertex Pharmaceuticals by 1.1% during the 4th quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company’s stock valued at $900,000 after acquiring an additional 24 shares during the period. Spinnaker Trust increased its stake in shares of Vertex Pharmaceuticals by 2.1% during the 4th quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company’s stock worth $497,000 after purchasing an additional 25 shares during the last quarter. Strategic Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 4th quarter. Strategic Advisors LLC now owns 4,486 shares of the pharmaceutical company’s stock worth $1,807,000 after purchasing an additional 25 shares during the period. Finally, Nicolet Advisory Services LLC lifted its stake in Vertex Pharmaceuticals by 4.6% in the third quarter. Nicolet Advisory Services LLC now owns 641 shares of the pharmaceutical company’s stock valued at $291,000 after purchasing an additional 28 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on VRTX. Royal Bank of Canada raised their target price on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 20th. HC Wainwright reissued a “buy” rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Stifel Nicolaus boosted their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a research note on Monday, December 16th. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $500.00 to $550.00 in a research report on Monday, December 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $506.70.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total transaction of $251,930.20. Following the transaction, the executive vice president now directly owns 58,539 shares of the company’s stock, valued at approximately $27,825,928.26. This trade represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 1,084 shares of company stock worth $505,512 in the last quarter. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $488.29 on Monday. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a fifty day moving average of $448.27 and a 200-day moving average of $461.15. The company has a market capitalization of $125.39 billion, a P/E ratio of -221.95, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.